These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

413 related items for PubMed ID: 22507372

  • 1. Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009.
    Gegia M, Cohen T, Kalandadze I, Vashakidze L, Furin J.
    Int J Tuberc Lung Dis; 2012 Jun; 16(6):812-6. PubMed ID: 22507372
    [Abstract] [Full Text] [Related]

  • 2. Isoniazid Monoresistance and Rate of Culture Conversion among Patients in the State of Georgia with Confirmed Tuberculosis, 2009-2014.
    Salindri AD, Sales RF, DiMiceli L, Schechter MC, Kempker RR, Magee MJ.
    Ann Am Thorac Soc; 2018 Mar; 15(3):331-340. PubMed ID: 29131662
    [Abstract] [Full Text] [Related]

  • 3. Clonal expansion of Mycobacterium tuberculosis isolates and coexisting drug resistance in patients newly diagnosed with pulmonary tuberculosis in Hanoi, Vietnam.
    Hung NV, Ando H, Thuy TT, Kuwahara T, Hang NT, Sakurada S, Thuong PH, Lien LT, Keicho N.
    BMC Res Notes; 2013 Nov 05; 6():444. PubMed ID: 24188178
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
    Chigutsa E, Pasipanodya JG, Visser ME, van Helden PD, Smith PJ, Sirgel FA, Gumbo T, McIlleron H.
    Antimicrob Agents Chemother; 2015 Jan 05; 59(1):38-45. PubMed ID: 25313213
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H.
    Kekkaku; 2003 Oct 05; 78(10):611-7. PubMed ID: 14621568
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Treatment outcome of new culture positive pulmonary tuberculosis in Norway.
    Farah MG, Tverdal A, Steen TW, Heldal E, Brantsaeter AB, Bjune G.
    BMC Public Health; 2005 Feb 07; 5():14. PubMed ID: 15698472
    [Abstract] [Full Text] [Related]

  • 14. Twice-weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: cohort study in rural South Africa.
    Davies GR, Connolly C, Sturm AW, McAdam KP, Wilkinson D.
    AIDS; 1999 May 07; 13(7):811-7. PubMed ID: 10357380
    [Abstract] [Full Text] [Related]

  • 15. Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa.
    van der Heijden YF, Karim F, Mufamadi G, Zako L, Chinappa T, Shepherd BE, Maruri F, Moosa MS, Sterling TR, Pym AS.
    Int J Tuberc Lung Dis; 2017 Jun 01; 21(6):670-676. PubMed ID: 28482962
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Results at 30 months of a randomised trial of two 8-month regimens for the treatment of tuberculosis.
    Nunn AJ, Jindani A, Enarson DA, Study A investigators.
    Int J Tuberc Lung Dis; 2011 Jun 01; 15(6):741-5. PubMed ID: 21575292
    [Abstract] [Full Text] [Related]

  • 18. Tuberculosis treatment outcome and predictors in northern Ethiopian prisons: a five-year retrospective analysis.
    Adane K, Spigt M, Dinant GJ.
    BMC Pulm Med; 2018 Feb 20; 18(1):37. PubMed ID: 29463234
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, Schall R, Spigelman M, Conradie A, Eisenach K, Venter A, Ive P, Page-Shipp L, Variava E, Reither K, Ntinginya NE, Pym A, von Groote-Bidlingmaier F, Mendel CM.
    Lancet; 2015 May 02; 385(9979):1738-1747. PubMed ID: 25795076
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.